Intralesional Bleomycin Injection and Skin Hyperpigmentation: A Case Series of a Single-Center Experience With a Standardized Skin-Protective Protocol.
Journal
A&A practice
ISSN: 2575-3126
Titre abrégé: A A Pract
Pays: United States
ID NLM: 101714112
Informations de publication
Date de publication:
05 Jan 2022
05 Jan 2022
Historique:
entrez:
6
1
2022
pubmed:
7
1
2022
medline:
8
1
2022
Statut:
epublish
Résumé
Bleomycin is a cytotoxic antibiotic that has a sclerosing effect on vascular endothelium. Small doses can be injected locally to reduce the size of various vascular malformations. Recognition that targeted intralesional injection carries the potential to cause hyperpigmentation, specifically in areas of skin trauma, and has led our department to implement a bleomycin skin-protective protocol. On review of cases performed following protocol implementation, no patients developed hyperpigmentation attributable to iatrogenic skin trauma. We present our bleomycin skin protection protocol to guide peer institutions in the initiation of similar quality improvement initiatives.
Identifiants
pubmed: 34989355
doi: 10.1213/XAA.0000000000001551
pii: 02054229-202201000-00001
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Bleomycin
11056-06-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e01551Informations de copyright
Copyright © 2021 International Anesthesia Research Society.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Mathur NN, Rana I, Bothra R, Dhawan R, Kathuria G, Pradhan T. Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck. Int J Pediatr Otorhinolaryngol. 2005;69:75–80.
Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: a review of intralesional applications. Dermatol Surg. 2008;34:1299–1313.
Milbar HC, Jeon H, Ward MA, Mitchell SE, Weiss CR, Cohen BA. Hyperpigmentation after foamed bleomycin sclerotherapy for vascular malformations. J Vasc Interv Radiol. 2019;30:1438–1442.
Yamamoto T. Bleomycin and the skin. Br J Dermatol. 2006;155:869–875.
Chen YB, Rahemtullah A, Breeden E, Hochberg EP. Bleomycin-induced flagellate erythema. J Clin Oncol. 2007;25:898–900.
Ziemer M, Goetze S, Juhasz K, Elsner P. Flagellate dermatitis as a bleomycin-specific adverse effect of cytostatic therapy: a clinical-histopathologic correlation. Am J Clin Dermatol. 2011;12:68–76.
Lee HY, Lim KH, Ryu Y, Song SY. Bleomycin-induced flagellate erythema: a case report and review of the literature. Oncol Lett. 2014;8:933–935.
Bowen B. Anaesthetic management of children with epidermolysis bullosa. BJA Education. 2017;18:41–45.
Nandi R, Howard R. Anesthesia and epidermolysis bullosa. Dermatol Clin. 2010;28:319–324.
Ibrahimi O, Anderson R. Bleomycin-induced flagellate hyperpigmentation. N Engl J Med. 2010;363:e36.
Abess DM, Keel BS. Graham. Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol. 2003;139:337–339.
Sainsbury DCG, Kessell G, Fall AJ, Hampton FJ, Guhan A, Muir T. Intralesional bleomycin injection treatment for vascular birthmarks: a 5-year experience at a single United Kingdom unit. Plast Reconstr Surg. 2011;127:2031–2044.
Horbach SER, Rigter IM, Smitt JHS, Reekers JA, Spuls PI, van der Horst CMAM. Intralesional bleomycin injections for vascular malformations: a systematic review and meta-analysis. Plast Reconstr Surg. 2016;137:244–256.
Mack JM, Richter GT, Becton D, Salem O, Hill SEM, Crary SE. Short-term side effects and patient-reported outcomes of bleomycin sclerotherapy in vascular malformations. Pediatr Blood Cancer. 2018;65:e27008.
Rubeiz NG, Salem Z, Dibbs R, Kibbi AG. Bleomycin-induced urticarial flagellate drug hypersensitivity reaction. Int J Dermatol. 1999;38:140–141.